207 related articles for article (PubMed ID: 33866491)
1. Targeting key transcriptional factor STAT3 in colorectal cancer.
Chalikonda G; Lee H; Sheik A; Huh YS
Mol Cell Biochem; 2021 Sep; 476(9):3219-3228. PubMed ID: 33866491
[TBL] [Abstract][Full Text] [Related]
2. Signal transducer and activator of transcription 3 - a promising target in colitis-associated cancer.
Pandurangan AK; Esa NM
Asian Pac J Cancer Prev; 2014; 15(2):551-60. PubMed ID: 24568457
[TBL] [Abstract][Full Text] [Related]
3. Cellular signaling pathways implicated in metastasis of colorectal cancer and the associated targeted agents.
Liu X; Ji Q; Fan Z; Li Q
Future Oncol; 2015; 11(21):2911-22. PubMed ID: 26414153
[TBL] [Abstract][Full Text] [Related]
4. LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis.
Wang H; Liu Z; Guan L; Li J; Chen S; Yu W; Lai M
Pharmacol Res; 2020 Mar; 153():104661. PubMed ID: 31982491
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer.
Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
Neoplasia; 2015 Sep; 17(9):687-696. PubMed ID: 26476076
[TBL] [Abstract][Full Text] [Related]
6. Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer.
Wu MM; Zhang Z; Tong CWS; Yan VW; Cho WCS; To KKW
Life Sci; 2020 Dec; 262():118522. PubMed ID: 33011217
[TBL] [Abstract][Full Text] [Related]
7. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway.
Ren D; Lin B; Zhang X; Peng Y; Ye Z; Ma Y; Liang Y; Cao L; Li X; Li R; Sun L; Liu Q; Wu J; Zhou K; Zeng J
Oncotarget; 2017 Jul; 8(30):49807-49823. PubMed ID: 28591704
[TBL] [Abstract][Full Text] [Related]
9. Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study.
Tantawy MA; El-Sherbeeny NA; Helmi N; Alazragi R; Salem N; Elaidy SM
Mol Cell Biochem; 2020 Jun; 469(1-2):143-157. PubMed ID: 32356241
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA DILC suppresses cell proliferation and metastasis in colorectal cancer.
Gu LQ; Xing XL; Cai H; Si AF; Hu XR; Ma QY; Zheng ML; Wang RY; Li HY; Zhang XP
Gene; 2018 Aug; 666():18-26. PubMed ID: 29621586
[TBL] [Abstract][Full Text] [Related]
11. LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo.
Liu Z; Wang H; Guan L; Lai C; Yu W; Lai M
Br J Pharmacol; 2020 Jan; 177(2):298-313. PubMed ID: 31499589
[TBL] [Abstract][Full Text] [Related]
12. CD133: An emerging prognostic factor and therapeutic target in colorectal cancer.
Akbari M; Shomali N; Faraji A; Shanehbandi D; Asadi M; Mokhtarzadeh A; Shabani A; Baradaran B
Cell Biol Int; 2020 Feb; 44(2):368-380. PubMed ID: 31579983
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8.
Wu T; Wang Z; Liu Y; Mei Z; Wang G; Liang Z; Cui A; Hu X; Cui L; Yang Y; Liu CY
Clin Immunol; 2014 Oct; 154(2):116-26. PubMed ID: 25063444
[TBL] [Abstract][Full Text] [Related]
14. Development of novel targeted agents in the treatment of metastatic colorectal cancer.
Berge E; Thompson C; Messersmith W
Clin Colorectal Cancer; 2011 Dec; 10(4):266-78. PubMed ID: 21903484
[TBL] [Abstract][Full Text] [Related]
15. Role of STAT3 signaling pathway in breast cancer.
Ma JH; Qin L; Li X
Cell Commun Signal; 2020 Feb; 18(1):33. PubMed ID: 32111215
[TBL] [Abstract][Full Text] [Related]
16. PAC exhibits potent anti-colon cancer properties through targeting cyclin D1 and suppressing epithelial-to-mesenchymal transition.
Al-Qasem A; Al-Howail HA; Al-Swailem M; Al-Mazrou A; Al-Otaibi B; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A
Mol Carcinog; 2016 Mar; 55(3):233-44. PubMed ID: 25641341
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis.
Ye TH; Yang FF; Zhu YX; Li YL; Lei Q; Song XJ; Xia Y; Xiong Y; Zhang LD; Wang NY; Zhao LF; Gou HF; Xie YM; Yang SY; Yu LT; Yang L; Wei YQ
Cell Death Dis; 2017 Jan; 8(1):e2534. PubMed ID: 28055016
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of SOCS3 and its biological function in colorectal cancer.
Chu Q; Shen D; He L; Wang H; Liu C; Zhang W
Gene; 2017 Sep; 627():114-122. PubMed ID: 28603075
[TBL] [Abstract][Full Text] [Related]
19. α7 nicotinic acetylcholine receptor in tumor-associated macrophages inhibits colorectal cancer metastasis through the JAK2/STAT3 signaling pathway.
Fei R; Zhang Y; Wang S; Xiang T; Chen W
Oncol Rep; 2017 Nov; 38(5):2619-2628. PubMed ID: 28901507
[TBL] [Abstract][Full Text] [Related]
20. Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer.
Kawada M; Seno H; Uenoyama Y; Sawabu T; Kanda N; Fukui H; Shimahara Y; Chiba T
Cancer Res; 2006 Mar; 66(6):2913-7. PubMed ID: 16540637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
